New hope for fabry patients: Long-Term drug study shows promise
Disease control
Ongoing
This study looks at the long-term safety and effectiveness of a drug called pegunigalsidase alfa for adults with Fabry disease, a rare genetic condition. Participants receive the drug through an IV every 4 weeks for an extended period. The goal is to see if the treatment remains …
Phase: PHASE3 • Sponsor: Chiesi Farmaceutici S.p.A. • Aim: Disease control
Last updated May 06, 2026 16:15 UTC